ArticlePloS one2007
Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas.
Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.Bioscience reports · 2020Pooled it
- Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies.International journal of molecular sciences · 2024Article
- Identification of New Molecular Biomarkers in Ovarian Cancer Using the Gene Expression Profile.Journal of clinical medicine · 2022Article
- Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance.Cellular and molecular neurobiology · 2022Article
- Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme.Frontiers in genetics · 2022Article
- Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass.Scientific reports · 2021Article
- p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer.Translational oncology · 2018Article
- A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence.Cold Spring Harbor perspectives in medicine · 2017Review
- Article
- Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines.Obstetrics and gynecology international · 2015Article
- Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.BMC cancer · 2014Article
- Article
- Power and stability properties of resampling-based multiple testing procedures with applications to gene oncology studies.Computational and mathematical methods in medicine · 2013Article
- Tumour suppressor genes in chemotherapeutic drug response.Bioscience reports · 2012Review
- Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC).PLoS computational biology · 2010Article
- Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy.Cancer research · 2009Article
- Yin yang 1 modulates taxane response in epithelial ovarian cancer.Molecular cancer research : MCR · 2009Article
- Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.Journal of translational medicine · 2008Article
- Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.PLoS medicine · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gene expression profiles of malignant tumors surgically removed from ovarian cancer patients pre-treated with chemotherapy (neo-adjuvant) prior to surgery group into two distinct clusters. One group clusters with carcinomas from patients not pre-treated with chemotherapy prior to surgery (C-L), while the other clusters with non-malignant adenomas (A-L). We show here that although the C-L cluster is preferentially associated with p53 loss-of-function (LOF) mutations, the C-L cluster cancer patients display a more favorable clinical response to chemotherapy as evidenced by enhanced long-term survivorships. Our results support a model whereby p53 mediated cell-cycle-arrest/DNA repair serves as a barrier to optimal chemotherapeutic treatment of ovarian and perhaps other carcinomas and suggest that inhibition of p53 during chemotherapy may enhance clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.